

Supplementary Material

Heteroatom exchange as a scaffold-editing strategy: a matched xanthone–acridone study of aminoalkyl derivatives

Agustina Gonzalez,^a A. Paula Irazoqui,^{ab} Claudia G. Buitrago,^{*ac} and Dario C. Gerbino^{*d}

^a Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 671, 8000 Bahía Blanca, Argentina. ^b Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC PBA), Argentina. ^c CCT-CONICET, Camino La Carrindanga km 7, 8000 Bahía Blanca, Argentina. ^d Instituto de Química del Sur, INQUISUR (CONICET-UNS). Departamento de Química, Universidad Nacional del Sur. Avenida Alem 1253, 8000 Bahía Blanca, Argentina

Email: cbuitrag@criba.edu.ar dgerbino@uns.edu.ar

Table of Contents

1. General information	S2
2. NMR spectra	S3

1. General experimental information

Reagents were obtained from commercial suppliers and used without further purification unless otherwise stated. Solvents were of commercial grade and distilled prior to use when required.

Thin-layer chromatography (TLC) was performed on silica gel 60 F254 plates, and compounds were visualized under UV irradiation and/or by staining with phosphomolybdic acid. Flash chromatography was performed using silica gel 60 (230–240 mesh ASTM).

Nuclear magnetic resonance (^1H and ^{13}C NMR) spectra were recorded at room temperature on a Bruker Avance ARX-300 spectrometer using CDCl_3 or $\text{DMSO}-d_6$ as solvents. Chemical shifts (δ) are reported in parts per million (ppm) relative to the residual solvent signals. Coupling constants (J) are reported in Hertz (Hz), and signal multiplicities are described using standard abbreviations.

Infrared spectra were obtained using a Nicolet Nexus 470 FT-IR instrument. Melting points were determined using a Büchi 510 apparatus and are uncorrected.

High-resolution mass spectra (HRMS) were recorded using Thermo Fisher LTQ Orbitrap XL and Finnigan MAT 95 spectrometers.

Characterization data for the synthesized intermediates and final aminoalkylated xanthone and acridone derivatives are provided in the following sections.

2. NMR Spectra




Figure 1. ^1H NMR (300 MHz, $\text{DMSO}-d_6$) spectrum of 1,3-dihydroxy-9H-xanthen-9-one (1,3-DHX).




Figure 2. ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) spectrum of 1,3-dihydroxy-9H-xanthen-9-one (1,3-DHX).




Figure 3. ¹H NMR (300 MHz, CDCl₃) spectrum of 3-((5-bromopentyl)oxy)-1-hydroxy-9H-xanthen-9-one (X5Br).




Figure 4. ¹³C NMR (75 MHz, CDCl₃) spectrum of 3-((5-bromopentyl)oxy)-1-hydroxy-9H-xanthen-9-one (X5Br).




Figure 5. ¹H NMR (300 MHz, CDCl₃) spectrum of 3-((5-(diethylamino)pentyl)oxy)-1-hydroxy-9H-xanthen-9-one (X5DE).




Figure 6. ¹³C NMR (75 MHz, CDCl₃) spectrum of 3-((5-(diethylamino)pentyl)oxy)-1-hydroxy-9H-xanthen-9-one (X5DE).





Figure 7. ¹H NMR (300 MHz, DMSO-*d*₆) spectrum of 1,3-dihydroxyacridin-9(10*H*)-one (1,3-DHA).






Figure 9. ¹H NMR (300 MHz, DMSO-*d*₆) spectrum of 3-((5-bromopentyl)oxy)-1-hydroxy-acridin-9(10*H*)-one (**A5Br**).




Figure 10. ¹³C NMR (75 MHz, DMSO-*d*₆) spectrum of 3-((5-bromopentyl)oxy)-1-hydroxy-acridin-9(10*H*)-one (**A5Br**).




Figure 11. ¹H NMR (300 MHz, CDCl₃) spectrum of 3-((5-(diethylamino)pentyl)oxy)-1-hydroxyacridin-9(10H)-one (A5DE).




Figure 12. ^{13}C NMR (75 MHz, CDCl_3) spectrum of 3-((5-(diethylamino)pentyl)oxy)-1-hydroxyacridin-9(10H)-one (**A5DE**).